Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection

References

• Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl 5):S344-9
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr. The management of infections due to drug-resistant Gram-positive bacteria. Eur J Clin Microbiol Infect Dis 2005;24(12):777-9
   PubMedGoogle Scholar
• Deresinski S. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert Rev Anti Infect Ther 2007;5(3):393-401
   PubMed Web of Science ®Google Scholar
• Rivera AM, Boucher HW. Current concepts in antimicrobial therapy against select Gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc 2011;86(12):1230-43
   PubMed Web of Science ®Google Scholar
• VIBATIV® [package insert]. Theravance Biopharma Antibiotics, Inc. 2014. Available from: www.vibativ.com/. [Last accessed 7 August 2014]
   Google Scholar
• Clinigen Healthcare Ltd. VIBATIV: summary of product characteristics. 2014. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/001240/WC500115364.pdf [Last accessed 6 August 2014]
   Google Scholar
• Health Canada. Summary basis of decision (SBD) for PRVIBATIV®. 2010. Available from: www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2010_vibativ_107792-eng.php [Last accessed 6 August 2014]
   Google Scholar
• Van Bambeke F, Van Laethem Y, Courvalin P, et al. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 2004;64(9):913-36
   PubMed Web of Science ®Google Scholar
• Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(3):1127-34
   PubMed Web of Science ®Google Scholar
• Breukink E, Humphrey PPA, Benton BM, et al. Evidence for a multivalent interaction between telavancin and membrane-bound lipid II. Presented at 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 27-30 September 2006
   Google Scholar
• Lunde CS, Rexer CH, Hartouni SR, et al. Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus. Antimicrob Agents Chemother 2010;54(5):2198-200
   PubMed Web of Science ®Google Scholar
• Lunde CS, Hartouni SR, Janc JW, et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009;53(8):3375-83
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009;49(12):1908-14
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Farrell DJ, et al. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. Antimicrob Agents Chemother 2012;56(7):3999-4004
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Jones RN. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008). Int J Antimicrob Agents 2010;36(4):374-9
   PubMedGoogle Scholar
• Mendes RE, Moet GJ, Janechek MJ, et al. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010;54(6):2704-6
   PubMedGoogle Scholar
• Pfaller MA, Rhomberg PR, Sader HS, et al. Telavancin activity against Gram-positive bacteria isolated from patients with skin and skin-structure infections. J Chemother 2010;22(5):304-11
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Mendes RE, Sader HS, et al. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother 2010;65(11):2396-404
   PubMedGoogle Scholar
• Mendes RE, Sader HS, Farrell DJ, et al. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007-2009). Diagn Microbiol Infect Dis 2012;72(1):113-17
   PubMedGoogle Scholar
• Mendes RE, Sader HS, Farrell DJ, et al. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010). Diagn Microbiol Infect Dis 2011;71(1):93-7
   PubMedGoogle Scholar
• Putnam SD, Sader HS, Moet GJ, et al. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagn Microbiol Infect Dis 2010;67(4):359-68
   PubMedGoogle Scholar
• Farrell DJ, Mendes RE, Rhomberg PR, et al. Revised Reference Broth Microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies. Antimicrob Agents Chemother 2014;58(9):5547-51
   PubMed Web of Science ®Google Scholar
• Mendes RE, Farrell DJ, Sader HS, et al. Baseline activity of telavancin when tested against gram-positive clinical isolates responsible for documented infections in USA Hospitals (2011-2012) Applying a Revised Susceptibility Testing Method. Presented at 114th General Meeting of the American Society for Microbiology (ASM). Boston, MA, USA, 17-20 May 2014
   Google Scholar
• Krause KM, Blais J, Lewis SR, et al. In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in Phase 3 clinical trials of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2012;74(4):429-31
   PubMedGoogle Scholar
• Krause KM, Renelli M, Difuntorum S, et al. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob Agents Chemother 2008;52(7):2647-52
   PubMedGoogle Scholar
• Leonard SN, Szeto YG, Zolotarev M, et al. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents 2011;37(6):558-61
   PubMedGoogle Scholar
• Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis 2012;55(4):582-6
   PubMed Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. CLSI M100-S24. Clinical Laboratory Standards Institute; Wayne, PA: 2014
   Google Scholar
• Hill CM, Krause KM, Lewis SR, et al. Specificity of induction of the VanA and VanB operons in vancomycin-resistant enterococci by telavancin. Antimicrob Agents Chemother 2010;54(7):2814-18
   PubMedGoogle Scholar
• Kosowska-Shick K, Clark C, Pankuch GA, et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob Agents Chemother 2009;53(10):4217-24
   PubMedGoogle Scholar
• Krause KM, Barriere SL, Kitt MM, et al. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 Phase 3 (ATLAS) clinical studies. Diagn Microbiol Infect Dis 2010;68(2):181-5
   PubMedGoogle Scholar
• Lin G, Pankuch GA, Ednie LM, et al. Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay. Antimicrob Agents Chemother 2010;54(5):2201-5
   PubMedGoogle Scholar
• Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47(11):3602-4
   PubMedGoogle Scholar
• Clouse FL, Hovde LB, Rotschafer JC. In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate. Antimicrob Agents Chemother 2007;51(12):4521-4
   PubMedGoogle Scholar
• Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 2005;56(2):337-43
   PubMed Web of Science ®Google Scholar
• LaPlante KL, Mermel LA. In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob Agents Chemother 2009;53(7):3166-9
   PubMed Web of Science ®Google Scholar
• Odenholt I, Löwdin E, Cars O. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother 2007;51(9):3311-16
   PubMed Web of Science ®Google Scholar
• Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58(6):1177-84
   PubMedGoogle Scholar
• Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis 2007;44(1):79-86
   PubMed Web of Science ®Google Scholar
• Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob Agents Chemother 2004;48(8):3043-50
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 2008;46(11):1683-93
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416
   PubMed Web of Science ®Google Scholar
• Lodise TP Jr, Gotfried M, Barriere S, et al. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2008;52(7):2300-4
   PubMedGoogle Scholar
• Reyes N, Skinner R, Kaniga K, et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;9(10):4344-6
   Google Scholar
• Crandon JL, Kuti JL, Nicolau DP. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob Agents Chemother 2010;54(12):5115-19
   PubMedGoogle Scholar
• Hegde SS, Reyes N, Skinner R, et al. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother 2008;61(1):169-72
   PubMedGoogle Scholar
• Gottfried MH, Shaw J-P, Benton BM, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother 2008;52(1):92-7
   PubMedGoogle Scholar
• Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis 2011;52(1):31-40
   PubMed Web of Science ®Google Scholar
• Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298(15):1763-71
   PubMed Web of Science ®Google Scholar
• Hegde SS, Difuntorum S, Skinner R, et al. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J Antimicrob Chemother 2009;63(4):763-6
   PubMedGoogle Scholar
• Hegde SS, Skinner R, Lewis SR, et al. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. J Antimicrob Chemother 2010(4):725-8
   PubMedGoogle Scholar
• Reyes N, Skinner R, Benton BM, et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58(2):462-5
   PubMedGoogle Scholar
• Thuny F, Grisoli D, Collart F, et al. Management of infective endocarditis: challenges and perspectives. Lancet 2012;379(9819):965-75
   PubMed Web of Science ®Google Scholar
• Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005(8):3163-5
   PubMedGoogle Scholar
• Miró JM, García-de-la-Mària C, Armero Y, et al. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2007;51(7):2373-7
   PubMedGoogle Scholar
• Xiong YQ, Hady WA, Bayer AS, et al. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2012;56(11):5528-33
   PubMed Web of Science ®Google Scholar
• van de Beek D. Progress and challenges in bacterial meningitis. Lancet 2012;380(9854):1623-4
   PubMed Web of Science ®Google Scholar
• Stucki A, Gerber P, Acosta F, et al. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 2006;50(2):770-3
   PubMed Web of Science ®Google Scholar
• Mruk AL, Record KE. Antimicrobial options in the treatment of adult staphylococcal bone and joint infections in an era of drug shortages. Orthopedics 2012;35(5):401-7
   PubMedGoogle Scholar
• Yin LY, Calhoun JH, Thomas TS, et al. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. J Antimicrob Chemother 2009;63(2):357-60
   PubMed Web of Science ®Google Scholar
• Darouiche RO. Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis 2001;33(9):1567-72
   PubMed Web of Science ®Google Scholar
• Darouiche RO, Mansouri MD, Schneidkraut MJ. Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits. Antimicrob Agents Chemother 2009;53(6):2626-8
   PubMed Web of Science ®Google Scholar
• Hornsey M, Longshaw C, Phee L, Wareham DW. In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Chemother 2012;56(6):3080-5
   PubMed Web of Science ®Google Scholar
• Hornsey M, Phee L, Longshaw C, et al. In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents 2013;41(3):285-7
   PubMed Web of Science ®Google Scholar
• Attwood RJ, LaPlante KL. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 2007;64(22):2335-48
   PubMedGoogle Scholar